Dabrafenib
About
Therapy type: Targeted therapy
Therapy strategy: B-RAF inhibition
Mappings
NCI Thesaurus: Dabrafenib (ncit:C82386)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) HC (1) | BRAF p.V600E | Melanoma | Dabrafenib | |
| FDA (4) | BRAF p.V600E | Melanoma | Dabrafenib, Trametinib | |
| FDA (4) | BRAF p.V600K | Melanoma | Dabrafenib, Trametinib | |
| FDA (2) HC (2) | BRAF p.V600E | Non-Small Cell Lung Cancer | Dabrafenib, Trametinib | |
| FDA (2) | BRAF p.V600E | Anaplastic Thyroid Cancer | Dabrafenib, Trametinib | |
| FDA (2) | BRAF p.V600E | Any solid tumor | Dabrafenib, Trametinib | |
| FDA (2) HC (2) | BRAF p.V600E | Low-Grade Glioma, NOS | Dabrafenib, Trametinib | |
| HC (2) | BRAF p.V600E | High-Grade Glioma, NOS | Dabrafenib, Trametinib | |
| HC (1) | BRAF p.V600K | Melanoma | Dabrafenib |